Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by SARS-CoV-2, lead to mild to severe respiratory illness and resulted in 6.9 million deaths worldwide. Although vaccines are effective in preventing COVID-19, they may not be sufficient to protect immunocompromised individuals from this respiratory illness. Moreover, novel emerging variants of SARS-CoV-2 pose a risk of new COVID-19 waves. Therefore, identification of effective antivirals is critical in controlling SARS and other coronaviruses, such as MERS-CoV. We show that Fangchinoline (Fcn)...
Source: Antiviral Research - November 10, 2023 Category: Virology Authors: Srikanth Sadhu Jyotsna Dandotiya Rajdeep Dalal Ritika Khatri Anna Z Mykytyn Aashima Batra Manpreet Kaur Rucha Chandwaskar Virendra Singh Aarzoo Kamboj Mitul Srivastava Shailendra Mani Shailendra Asthana Sweety Samal Zaigham Abbas Rizvi Deepak B Salunke Ba Source Type: research
Induction of neutralizing antibodies and mucosal IgA through intranasal immunization with the receptor binding domain of SARS-CoV-2 spike protein fused with the type IIb E. coli heat-labile enterotoxin A subunit
Antiviral Res. 2023 Nov 8:105752. doi: 10.1016/j.antiviral.2023.105752. Online ahead of print.ABSTRACTThe outbreak of SARS-CoV-2 infections had led to the COVID-19 pandemic which has a significant impact on global public health and the economy. The spike (S) protein of SARS-CoV-2 contains the receptor binding domain (RBD) which binds to human angiotensin-converting enzyme 2 receptor. Numerous RBD-based vaccines have been developed and recently focused on the induction of neutralizing antibodies against the immune evasive Omicron BQ.1.1 and XBB.1.5 subvariants. In this preclinical study, we reported the use of a direct fusi...
Source: Antiviral Research - November 10, 2023 Category: Virology Authors: He-Chin Hsieh Chung-Chu Chen Pin-Han Chou Wen-Chun Liu Suh-Chin Wu Source Type: research
Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
Antiviral Res. 2023 Nov 8:105743. doi: 10.1016/j.antiviral.2023.105743. Online ahead of print.ABSTRACTThe COVID-19 pandemic caused by SARS-CoV-2, lead to mild to severe respiratory illness and resulted in 6.9 million deaths worldwide. Although vaccines are effective in preventing COVID-19, they may not be sufficient to protect immunocompromised individuals from this respiratory illness. Moreover, novel emerging variants of SARS-CoV-2 pose a risk of new COVID-19 waves. Therefore, identification of effective antivirals is critical in controlling SARS and other coronaviruses, such as MERS-CoV. We show that Fangchinoline (Fcn)...
Source: Antiviral Research - November 10, 2023 Category: Virology Authors: Srikanth Sadhu Jyotsna Dandotiya Rajdeep Dalal Ritika Khatri Anna Z Mykytyn Aashima Batra Manpreet Kaur Rucha Chandwaskar Virendra Singh Aarzoo Kamboj Mitul Srivastava Shailendra Mani Shailendra Asthana Sweety Samal Zaigham Abbas Rizvi Deepak B Salunke Ba Source Type: research
A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants
We present a bivalent Receptor Binding Domain (RBD)-specific synthetic antibody, specific for the RBD of wild-type (lineage A), developed from a non-antibody protein scaffold composed of LRR (Leucine-rich repeat) modules through phage display. We further reinforced the unique feature of the synthetic antibody by constructing a tandem dimeric form. The resulting bivalent form showed a broader neutralizing activity against the variants. The in vivo neutralizing efficacy of the bivalent synthetic antibody was confirmed using a human ACE2-expressing mouse model that significantly alleviated viral titer and lung infection. The ...
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Dong-Gun Kim Uijin Kim In Ho Park Bumhan Ryu Youngki Yoo Jeong Seok Cha Ga-Yeon Yoon Sung-Hee Kim Heeju Oh Jun-Young Seo Ki Taek Nam Je Kyung Seong Jeon-Soo Shin Hyun-Soo Cho Hak-Sung Kim Source Type: research
Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization
Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744. Online ahead of print.ABSTRACTWorking with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is restricted to biosafety level III (BSL-3) laboratory. The study used a trans-complementation system consisting of virus-like particles (VLPs) and DNA-launched replicons to generate SARS-CoV-2 single-round infectious particles (SRIPs) with variant-specific spike (S) proteins. S gene of Wuhan-Hu-1 strain (SWH1) or Omicron BA.1 variant (SBA.1), along with the envelope (E) and membrane (M) genes, were cloned into a tricistronic vector, co-expressed in...
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Wen-Chi Su Zan-Yu Chen Young-Sheng Chang King-Song Jeng Uyen Nguyen Phuong Le Yu-Chi Chou Li-Lan Kuo Ivonne Melano None Jesse Wei-Jan Wang Ying-Chyi Song Sin-Rong Li Mien-Chie Hung Michael M C Lai Cheng-Wen Lin Source Type: research
Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV
In this study, we took a rational and iterative approach to develop a series of baicalein derivatives with improved antiviral activity against Dengue virus (DENV). Compound 11064 emerged as a promising lead candidate, exhibiting antiviral activity against the four DENV serotypes and representative strains of Zika virus (ZIKV) in vitro, with attractive selectivity indices. Mechanistic studies revealed that Compound 11064 did not prevent DENV attachment at the cell surface, nor viral RNA synthesis and viral protein translation. Instead, the drug was found to impair the post-receptor binding entry steps (endocytosis and/or un...
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Geraldine Nadya Putri Chandra Sekhar Gudla Mayas Singh Chin Huan Ng Fakhriedzwan Fitri Haji Idris Yukei Oo Tan Hwee Yee Jasmine Wong Jie Feng Joel Justin Jang Hann Chu Vignesh Selvam Siva Shanmugam Selvaraj Radha Krishan Shandil Shridhar Narayanan Sylvie Source Type: research
Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?
CONCLUSIONS: We documented 7.8% rate of patients with detectable HCV RNA at the ET, of whom 89% subsequently achieved SVR, significantly more frequently in the population treated with pangenotypic regimens. Less severe liver disease, more often GT3 infection, and a higher percentage of treatment-naive patients distinguished this group from non-responders.PMID:37944825 | DOI:10.1016/j.antiviral.2023.105742 (Source: Antiviral Research)
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Dorota Zar ębska-Michaluk Robert Flisiak Ewa Janczewska Hanna Berak W łodzimierz Mazur Justyna Janocha-Litwin Rafa ł Krygier Beata Dobracka Jerzy Jaroszewicz Anna Parfieniuk-Kowerda Krystyna Dobrowolska Piotr Rzymski Source Type: research
A bivalent form of a RBD-specific synthetic antibody effectively neutralizes SARS-CoV-2 variants
We present a bivalent Receptor Binding Domain (RBD)-specific synthetic antibody, specific for the RBD of wild-type (lineage A), developed from a non-antibody protein scaffold composed of LRR (Leucine-rich repeat) modules through phage display. We further reinforced the unique feature of the synthetic antibody by constructing a tandem dimeric form. The resulting bivalent form showed a broader neutralizing activity against the variants. The in vivo neutralizing efficacy of the bivalent synthetic antibody was confirmed using a human ACE2-expressing mouse model that significantly alleviated viral titer and lung infection. The ...
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Dong-Gun Kim Uijin Kim In Ho Park Bumhan Ryu Youngki Yoo Jeong Seok Cha Ga-Yeon Yoon Sung-Hee Kim Heeju Oh Jun-Young Seo Ki Taek Nam Je Kyung Seong Jeon-Soo Shin Hyun-Soo Cho Hak-Sung Kim Source Type: research
Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization
Antiviral Res. 2023 Nov 7:105744. doi: 10.1016/j.antiviral.2023.105744. Online ahead of print.ABSTRACTWorking with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is restricted to biosafety level III (BSL-3) laboratory. The study used a trans-complementation system consisting of virus-like particles (VLPs) and DNA-launched replicons to generate SARS-CoV-2 single-round infectious particles (SRIPs) with variant-specific spike (S) proteins. S gene of Wuhan-Hu-1 strain (SWH1) or Omicron BA.1 variant (SBA.1), along with the envelope (E) and membrane (M) genes, were cloned into a tricistronic vector, co-expressed in...
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Wen-Chi Su Zan-Yu Chen Young-Sheng Chang King-Song Jeng Uyen Nguyen Phuong Le Yu-Chi Chou Li-Lan Kuo Ivonne Melano None Jesse Wei-Jan Wang Ying-Chyi Song Sin-Rong Li Mien-Chie Hung Michael M C Lai Cheng-Wen Lin Source Type: research
Expanding the anti-flaviviral arsenal: Discovery of a baicalein-derived Compound with potent activity against DENV and ZIKV
In this study, we took a rational and iterative approach to develop a series of baicalein derivatives with improved antiviral activity against Dengue virus (DENV). Compound 11064 emerged as a promising lead candidate, exhibiting antiviral activity against the four DENV serotypes and representative strains of Zika virus (ZIKV) in vitro, with attractive selectivity indices. Mechanistic studies revealed that Compound 11064 did not prevent DENV attachment at the cell surface, nor viral RNA synthesis and viral protein translation. Instead, the drug was found to impair the post-receptor binding entry steps (endocytosis and/or un...
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Geraldine Nadya Putri Chandra Sekhar Gudla Mayas Singh Chin Huan Ng Fakhriedzwan Fitri Haji Idris Yukei Oo Tan Hwee Yee Jasmine Wong Jie Feng Joel Justin Jang Hann Chu Vignesh Selvam Siva Shanmugam Selvaraj Radha Krishan Shandil Shridhar Narayanan Sylvie Source Type: research
Does a detectable HCV RNA at the end of DAA therapy herald treatment failure?
CONCLUSIONS: We documented 7.8% rate of patients with detectable HCV RNA at the ET, of whom 89% subsequently achieved SVR, significantly more frequently in the population treated with pangenotypic regimens. Less severe liver disease, more often GT3 infection, and a higher percentage of treatment-naive patients distinguished this group from non-responders.PMID:37944825 | DOI:10.1016/j.antiviral.2023.105742 (Source: Antiviral Research)
Source: Antiviral Research - November 9, 2023 Category: Virology Authors: Dorota Zar ębska-Michaluk Robert Flisiak Ewa Janczewska Hanna Berak W łodzimierz Mazur Justyna Janocha-Litwin Rafa ł Krygier Beata Dobracka Jerzy Jaroszewicz Anna Parfieniuk-Kowerda Krystyna Dobrowolska Piotr Rzymski Source Type: research
Artificial intelligence: Machine learning approach for screening large database and drug discovery
Antiviral Res. 2023 Nov 5:105740. doi: 10.1016/j.antiviral.2023.105740. Online ahead of print.ABSTRACTRecent research in drug discovery dealing with many faces difficulties, including development of new drugs during disease outbreak and drug resistance due to rapidly accumulating mutations. Virtual screening is the most widely used method in computer aided drug discovery. It has a prominent ability in screening drug targets from large molecular databases. Recently, a number of web servers have developed for quickly screening publicly accessible chemical databases. In a nutshell, deep learning algorithms and artificial neur...
Source: Antiviral Research - November 7, 2023 Category: Virology Authors: Prachi P Parvatikar Sudha Patil Kedar Khaparkhuntikar Shruti Patil Pankaj K Singh R Sahana Raghavendra V Kulkarni Anjanapura V Raghu Source Type: research
Artificial intelligence: Machine learning approach for screening large database and drug discovery
Antiviral Res. 2023 Nov 5:105740. doi: 10.1016/j.antiviral.2023.105740. Online ahead of print.ABSTRACTRecent research in drug discovery dealing with many faces difficulties, including development of new drugs during disease outbreak and drug resistance due to rapidly accumulating mutations. Virtual screening is the most widely used method in computer aided drug discovery. It has a prominent ability in screening drug targets from large molecular databases. Recently, a number of web servers have developed for quickly screening publicly accessible chemical databases. In a nutshell, deep learning algorithms and artificial neur...
Source: Antiviral Research - November 7, 2023 Category: Virology Authors: Prachi P Parvatikar Sudha Patil Kedar Khaparkhuntikar Shruti Patil Pankaj K Singh R Sahana Raghavendra V Kulkarni Anjanapura V Raghu Source Type: research
Artificial intelligence: Machine learning approach for screening large database and drug discovery
Antiviral Res. 2023 Nov 5:105740. doi: 10.1016/j.antiviral.2023.105740. Online ahead of print.ABSTRACTRecent research in drug discovery dealing with many faces difficulties, including development of new drugs during disease outbreak and drug resistance due to rapidly accumulating mutations. Virtual screening is the most widely used method in computer aided drug discovery. It has a prominent ability in screening drug targets from large molecular databases. Recently, a number of web servers have developed for quickly screening publicly accessible chemical databases. In a nutshell, deep learning algorithms and artificial neur...
Source: Antiviral Research - November 7, 2023 Category: Virology Authors: Prachi P Parvatikar Sudha Patil Kedar Khaparkhuntikar Shruti Patil Pankaj K Singh R Sahana Raghavendra V Kulkarni Anjanapura V Raghu Source Type: research
Tiratricol inhibits yellow fever virus replication through targeting viral RNA-dependent RNA polymerase of NS5
Antiviral Res. 2023 Oct 24;219:105737. doi: 10.1016/j.antiviral.2023.105737. Online ahead of print.ABSTRACTYellow fever virus (YFV) infection is a major public concern that threatens a large population in South America and Africa. No specific antiviral drugs are available for treating yellow fever. Here, we report that tiratricol (triiodothyroacetic acid, TRIAC), a clinically approved drug used to treat thyroid hormone resistance syndrome (THRS), is a potent YFV inhibitor both in host cells and in animal models.An in vitro study demonstrates that TRIAC remarkably suppresses viral RNA synthesis and protein expression in a d...
Source: Antiviral Research - October 25, 2023 Category: Virology Authors: Hao Ren Jiaqi Wang Hailin Tang Xijing Qian Binghui Xia Zhenghan Luo Zhenghao Xu Zhongtian Qi Ping Zhao Source Type: research
